Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- Confavreux, Christian
- O'Connor, Paul
- Comi, Giancarlo
- Freedman, Mark S
- Miller, Aaron E
- Olsson, Tomas P
- Wolinsky, Jerry S
- Bagulho, Teresa
- Delhay, Jean-Luc
- Dukovic, Deborah
- Truffinet, Philippe
- TOWER Trial Group
- Kappos, Ludwig
Publication date
March 2014
DOI Publisher
Lancet Pub. Group ISSN
1474-4422 Journal
issn:1474-4465Abstract
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis. We aimed to provide further evidence for the safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis.status: publishe
Add to ORKG